Literature DB >> 25820172

Confirmation of Pig-a mutation in flow cytometry-identified CD48-deficient T-lymphocytes from F344 rats.

Javier Revollo1, Mason G Pearce1, Dayton M Petibone1, Roberta A Mittelstaedt1, Vasily N Dobrovolsky2.   

Abstract

The Pig-a assay is used for monitoring somatic cell mutation in laboratory animals and humans. The assay detects haematopoietic cells deficient in glycosylphosphatidylinositol (GPI)-anchored protein surface markers using flow cytometry. However, given that synthesis of the protein markers (and the expression of their genes) is independent of the expression of the X-linked Pig-a gene and the function of its enzyme product, the deficiency of markers at the surface of the cells may be caused by a number of events (e.g. by mutation or epigenetic silencing in the marker gene itself or in any of about two dozen autosomal genes involved in the synthesis of GPI). Here we provide direct evidence that the deficiency of the GPI-anchored surface marker CD48 in rat T-cells is accompanied by mutation in the endogenous X-linked Pig-a gene. We treated male F344 rats with N-ethyl-N-nitrosourea (ENU), and established colonies from flow cytometry-identified and sorted CD48-deficient spleen T-lymphocytes. Molecular analysis confirmed that the expanded sorted cells have mutations in the Pig-a gene. The spectrum of Pig-a mutation in our model was consistent with the spectrum of ENU-induced mutation determined in other in vivo models, mostly base-pair substitutions at A:T with the mutated T on the non-transcribed strand of Pig-a genomic DNA. We also used next generation sequencing to derive a similar mutational spectrum from a pool of 64 clones developed from flow-sorted CD48-deficient lymphocytes. Our findings confirm that Pig-a assays detect what they are designed to detect-gene mutation in the Pig-a gene.
© The Author 2015. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25820172     DOI: 10.1093/mutage/geu030

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  4 in total

1.  Pig-a gene mutation assay study design: critical assessment of 3- versus 28-day repeat-dose treatment schedules.

Authors:  Azeddine Elhajouji; Tamsanqa Tafara Hove; Oliver O'Connell; Hansjoerg Martus; Stephen D Dertinger
Journal:  Mutagenesis       Date:  2020-09-12       Impact factor: 3.000

2.  In vivo pig-a and micronucleus study of the prototypical aneugen vinblastine sulfate.

Authors:  Svetlana L Avlasevich; Carson Labash; Dorothea K Torous; Jeffrey C Bemis; James T MacGregor; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2017-08-19       Impact factor: 3.216

3.  Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma.

Authors:  Hasan N Haboubi; Rachel L Lawrence; Benjamin Rees; Lisa Williams; James M Manson; Neam Al-Mossawi; Owen Bodger; Paul Griffiths; Catherine Thornton; Gareth J Jenkins
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

4.  Development of an in vitro PIG-A gene mutation assay in human cells.

Authors:  Benjamin J Rees; Matthew Tate; Anthony M Lynch; Catherine A Thornton; Gareth J Jenkins; Richard M Walmsley; George E Johnson
Journal:  Mutagenesis       Date:  2017-03-01       Impact factor: 2.954

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.